Sickle cell disease trials recruiting in Maryland

All Sickle cell disease trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Maryland: Baltimore
• Blood Sampling for Research Related to Sickle Cell Disease
  NCT00542230 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Bethesda
• Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
  NCT03937817 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Bethesda
• Cooperative Assessment of Late Effects for SCD Curative Therapies
  NCT05153967 · Phase: Not specified · Ages: 4 Years to 65 Years · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
  NCT06313398 · Phase: Early Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Bethesda
• Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
  NCT05170412 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
  NCT07566494 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · Maryland: Bethesda
• Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
  NCT03685721 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · Maryland: Bethesda
• Natural History of Sickle Cell Disease
  NCT00081523 · Phase: Not specified · Ages: 2 Years to 90 Years · Sex: All (male and female) · Maryland: Bethesda
• Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
  NCT05213572 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Bethesda
• Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
  NCT07599176 · Phase: Phase 1, Phase 2 · Ages: 4 Years to 65 Years · Sex: All (male and female) · Maryland: Bethesda
• Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
  NCT04008368 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 80 Years · Sex: All (male and female) · Maryland: Bethesda
• SCD Stem Cell Mobilization and Apheresis Using Motixafortide
  NCT06442761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
  NCT05904093 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Maryland: Bethesda
• Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
  NCT06944067 · Phase: Not specified · Ages: 2 Years to 99 Years · Sex: All (male and female) · Maryland: Bethesda
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · Maryland: Baltimore
• Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
  NCT06184126 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore